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Abstract Understanding the mechanisms of neuronal dys-
function and death represents a major frontier in contemporary
medicine, involving the acute cell death in stroke, and the
attrition of the major neurodegenerative diseases, including
Parkinson's, Alzheimer's, Huntington's and Motoneuron dis-
eases. A growing body of evidence implicates mitochondrial
dysfunction as a key step in the pathogenesis of all these
diseases, with the promise that mitochondrial processes rep-
resent valuable potential therapeutic targets. Each disease is
characterised by the loss of a specific vulnerable population of
cells—dopaminergic neurons in Parkinson's disease, spinal
motoneurons inMotoneuron disease, for example.We discuss
the possible roles of cell type-specific calcium signalling
mechanisms in defining the pathological phenotype of
each of these major diseases and review central mech-
anisms of calcium-dependent mitochondrial-mediated
cell death.
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Introduction
The fine spatial and temporal organisation of intracellular
calcium signals is fundamental to function in the CNS, perhaps
more than in any other tissue. Signals are conveyed throughout
the CNS by local changes in calcium concentration ([Ca2+]c)
carrying information from neuron to neuron, between neurons
and glia and even regulating local blood flow in relation to
local activity. Local changes in [Ca2+]c are the very stuff of our
thoughts and sensations, our memories and dreams. Neuronal
energy supplies are meanwhile entirely predicated on mito-
chondrial oxidative phosphorylation—neurons are almost
exclusively dependent on mitochondrial ATP generation and
have almost no capacity to upregulate energy supply through
glycolysis when oxidative phosphorylation is compromised
[33], making them especially vulnerable to mitochondrial dys-
function. Mitochondrial function and Ca2+ signalling are inti-
mately linked, as the [Ca2+]c signal is used as the major
medium of a continuous subtle dialogue between the cytosol
and its mitochondrial population that regulates energy
homeostasis. It is the [Ca2+]c signal that signals to mitochon-
dria that more energy is required, and the [Ca2+]c signal that
mediates the mechanisms that deliver increased energy. [Ca2+]c
signals even tell mitochondria where to go in the labyrinthine
maze of a complex neuron.
These mechanisms are so fundamental, that even subtle
disturbances are likely to have far reaching functional con-
sequences in disease. Defects in mitochondrial function are
now implicated in a litany of major diseases throughout the
CNS. Development of irreversible mitochondrial injury is
almost certainly the critical step in the pathway to irrevers-
ible injury and cell death in the penumbra of an evolving
stroke. Chronic defects in aspects of mitochondrial biology
have been linked with most of the major neurodegenerative
diseases. These include a range of genetic diseases—
Huntington's disease and Friedreich's ataxia, some of the
cerebellar ataxias, and heritable, familial forms of Parkin-
sons' disease, Motoneuron disease (also known as amyotro-
phic lateral sclerosis (ALS)) and Alzheimer's disease. These
latter three diseases are unusual in this respect, as almost
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identical disease phenotypes are seen both as sporadic forms
for which risk increases progressively with age, and as
heritable familial forms, in which mutations of specific
genes lead to almost identical disease phenotypes that usu-
ally occur in a younger age group of patients. The evidence
for a mitochondrial pathophysiology is stronger in some of
these diseases than in others, and a major challenge remains
to define the processes that are primary mechanisms driving
the pathophysiology, those which are contributors on the
pathways to cell injury caused by other primary processes,
and those that are epiphenomena, and ultimately to identify
potentially useful therapeutic targets. These diseases are of
huge importance as a major frontier in medical research, a
major challenge to the pharmaceutical industry, and an
enormous and terrifying threat to us all.
In this short essay, I will explore in particular the role of
mitochondrial Ca2+ handling in neurons in the pathophysi-
ology of these horrible and disabling diseases, with a focus
on Ca2+-mediated cell death as a most extreme form of
mitopathy that seems potentially tractable to therapeutic
intervention, and that seems also to represent a ubiquitous
form of cell injury that is recapitulated in many different
disease contexts.
Mitochondrial calcium handling in the CNS
One of the abiding and critical unanswered questions in all
the major neurodegenerative diseases is the basis for the
selectivity and specificity of the cellular targets of degener-
ation: the death of motoneurons in ALS, of Purkinje neurons
in the cerebellar ataxias, of dopaminergic neurons of the
substantia nigra in Parkinson's disease (PD) and of retinal
ganglion cells in optic atrophy and Leber's hereditary optic
neuropathy. This is most difficult in those genetic diseases
for which mutations of proteins have been identified, as, in
all of these, the mutant proteins are ubiquitously expressed
while only the target cells are affected. This signals a search
for mechanisms or features of the target cells that makes
them especially vulnerable to the effects of the mutation, but
it has to be said that the questions remain in the most part
unsatisfactorily answered if answered at all.
There is growing evidence that the answer, at least in
some cases, may be embedded in the cell-specific aspects of
mitochondrial Ca2+ signalling—the overall theme of this
special issue. This theme is perfectly exemplified in the
CNS, where there is a striking diversity in the [Ca2+]c
signalling pathways employed by different cell populations.
Indeed, it seems very plausible that the differences in ex-
pression of specific elements in the [Ca2+]c-signalling tool-
kit may be, at least in part, responsible for the cell type
specificity of injury seen in most of the neurodegenerative
diseases.
Calcium signalling in neurons is, in general, dominated
by Ca2+ influx through voltage- and ligand-gated ion chan-
nels, with smaller modulations by intracellular signalling
pathways, while [Ca2+]c signalling in glial cells is dominated
by Ca2+ release from ER using IP3 as a second messenger
system. This very crude classification leads to further sub-
specialisations, depending on the classes of ion channels
expressed by the neurons, neuronal architecture, cell size,
Ca2+ buffering power and patterns of excitability. Thus, the
specific Ca2+ signalling physiology of a cerebellar Purkinje
cell is radically different from that of the neighbouring cere-
bellar granule cell, although both are ‘neurons’, reflecting
differences in size and complexity and the requirement for
local amplifying signalling mechanisms. Spinal motoneurons
differ in many respects from many other cell types in their
large volume, their enormously long axons and in their ex-
pression of Ca2+ permeant ‘AMPA’ subclass of glutamate
receptors [13], combined, apparently with a relatively low
Ca2+ buffering power [29, 54]. The dopaminergic neurons of
the substantia nigra that selectively degenerate in PD have an
unusual physiology in terms of their repetitive rhythmic ex-
citability driven by pacemaking L-type Ca2+ channels [64].
Amongst the glia, astrocyte, microglial and oligodendrocyte
Ca2+ signalling are all different, still to be fully explored and
beyond the scope of this review.
Calcium regulates local mitochondrial metabolism
While much of the early literature demonstrating pathways
for physiological mitochondrial Ca2+ accumulation and ex-
trusion arose from studies of isolated mitochondria from
liver or heart, it turns out that many of the earliest demon-
strations of physiological mitochondrial Ca2+ uptake came
from neuronal systems. A recurrent theme throughout this
special issue is the activation of mitochondrial metabolism
through the stimulation of the tricarboxylic acid (TCA)
cycle by a rise in the matrix Ca2+ concentration [48]. One
of the earliest demonstrations that a rise in Ca2+ concentra-
tion can increase mitochondrial oxidative phosphorylation
was made in the photoreceptor, albeit from that strangest of
creatures, the horseshoe crab [24] nearly a quarter of a
century ago. Around the same time, Thayer and colleagues
showed that during the time period immediately following
(but not before) generation of Ca2+ signals through physio-
logical pathways (although admittedly not to stimuli that
could be called very physiological) in sensory neurons, the
collapse of mitochondrial membrane potential by an uncou-
pler caused a large Ca2+ signal, presumably due to the
release of Ca2+ from mitochondria, inferring that the mito-
chondria had been Ca2+ loaded by the prior Ca2+ increase,
i.e. the mitochondria were accumulating Ca2+ during a
physiological stimulus, a controversial issue at that time
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[66]. This was followed by our own work, also in sensory
neurons, showing changes in mitochondrial function—a
brief transient mitochondrial depolarization associated with
mitochondrial Ca2+ uptake across the inner membrane, fol-
lowed by prolonged, Ca2+-dependent increase in NADH—
following depolarization-induced Ca2+ signals also in sen-
sory neurons, again with the inference that mitochondria
must be taking up Ca2+ under these physiological condi-
tions. The interpretation was that mitochondria were taking
up Ca2+, which activated the TCA cycle, increasing NADH
and driving increased oxidative phosphorylation [22]. Even
in complex preparations of neuronal networks, such as the
hippocampal slice preparation, stimulation of synaptic path-
ways led to Ca2+-dependent changes in NADH fluorescence
suggesting direct modulation of metabolism by Ca2+ signals
[38, 60]. Thus, the Ca2+ signals that are essential for synap-
tic transmission and therefore for transmission of informa-
tion throughout the CNS are transmitted to the mitochondria
where it is assumed that Ca2+ modulates mitochondrial
metabolism as described elsewhere—with upregulation of
the TCA cycle, of the ATP synthase, of the aspartate carrier
[56] and presumably with a resultant increase in the supply
of ATP. I am intentionally cautious here, as a formal direct
demonstration of increased ATP generation in neurons in
response to synaptic stimulation is lacking as yet, although
this has been demonstrated in other cell types [37].
If mitochondria take up Ca2+, it follows that they have a
potential to act as local Ca2+ buffers. The effective impact is
a quantitative matter—how densely packed are the mito-
chondria and what is their capacity to accumulate Ca2+?
There are good data to show that mitochondrial Ca2+ uptake
has a sufficient impact on local Ca2+ signalling to help shape
synaptic transmission, both at the neuromuscular junction
[18, 19] and at the giant synapse of the calyx of Held [8].
We also showed that mitochondrial Ca2+ uptake has suffi-
cient buffering power to determine the rate of propagation of
Ca2+ signals as waves through astrocytes [9]. As the subtle
shaping and the spatial and temporal characteristics of Ca2+
signals are essential in shaping neuronal activity, it is very
tempting to speculate that this subtle impact will be altered
in disease states in which mitochondrial function is dis-
turbed, having a disproportionate impact on CNS function.
This remains hard to study directly and remains largely
speculative.
Calcium directs the mitochondrial traffic
Calcium signals also seem to play a critical role in directing
the mitochondrial traffic in complex neuronal networks.
Mitochondria must be continually refreshed with new mito-
chondrial protein (the vast bulk of which is encoded by
nuclear DNA), and must then be transported sometimes very
long distances along axonal routes to reach the synaptic
terminals where they are most needed. Travelling mitochon-
dria have to find their way through complex dendritic trees
and up and down long axons in a cell that may be effectively
a metre long. Trafficking in general is beyond the scope of
this review, but in principle involves the interaction between
proteins on the outer mitochondrial membrane, including
mitofusin 2 (MFN2) and the Ca2+-dependent Miro1. The
local positioning of mitochondria near points of high energy
demand seems functionally important and appears to be
largely orchestrated by Ca2+. Thus, a local rise in [Ca2+]c
interacts with the outer mitochondrial protein Miro, inhibit-
ing trafficking through the kinesin motor KIF5, so that
mitochondria stop where they are, and remain localized at
areas where [Ca2+]c is high—presumably the places where
energy demand will be highest and where local Ca2+ buff-
ering is also likely to be important [44]. Defects in axonal
mitochondrial transport lead to long tract dysfunction, such
as the Charcot Marie Tooth peripheral sensory neuropathy
(type 2A) that involves a defect in the protein MFN2 which
interacts with Miro1 and 2 [50]. Defects in mitochondrial
trafficking proteins have also been associated with Parkin-
son's disease. The kinase PTEN induced kinase 1 (PINK1)
is one of an increasingly large family of proteins for which
mutations are associated with familial forms of PD (see also
below). PINK1 expression on the outer mitochondrial mem-
brane increases in depolarized mitochondria, and recruits
the ubiquitin ligase Parkin to mitochondria, promoting mi-
tochondrial autophagy (mitophagy). It turns out that PINK1
phosphorylates Miro, activating its proteosomal degradation
through the PINK1-dependent recruitment of Parkin. It is
proposed that degradation of Miro limits mitochondrial
movement, and might serve to ‘quarantine damaged mito-
chondria’, prior to their removal by autophagy with the
suggestion that mutations in these proteins will impair the
processes that segregate and remove dysfunctional mito-
chondria, allowing their accumulation and so leading to
progressive neurodegeneration [50]. Defective axonal trans-
port of mitochondria has also been associated with Moto-
neuron disease (discussed briefly below).
Roles of mitochondria in calcium-dependent
neurotoxicity
A decisive element in the neuronal signalling machinery is
the expression of the glutamate receptor families. Of these,
two are highly Ca2+ permeable—the NMDA receptor and
the Ca2+-permeant AMPA receptor. These play a crucial role
in regulating Ca2+ influx related to synaptic activity and
modulation, but they also create a precarious balancing act
for neuronal Ca2+ homeostasis. It has been apparent for
many years that prolonged exposure of neurons in culture
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to high concentrations of glutamate leads to Ca2+-dependent
cell death—a phenomenon described as excitotoxicity [16].
Not only was it clear that glutamate caused Ca2+-dependent
toxicity but it also seemed that not all Ca2+ is the same—the
toxicity of Ca2+ depends on the route of entry. Michael
Tymianski coined the term ‘the source specificity’ of Ca2+-
dependent toxicity, showing that Ca2+ influx into hippocam-
pal neurons via L-type voltage-gated Ca2+ channels was
innocuous, while a similar global Ca2+ load (measured using
radiolabelled calcium to avoid artefacts due to dye satura-
tion) arriving in the cell through NMDA receptors was lethal
[67]. His group later went on to show in a most elegant
series of experiments that the source specificity arises from
the colocalisation of NMDA receptors with nNOS, coupled
through the post synaptic density protein, psd-95 [58]. The
Ca2+-dependent nNOS was thus exposed to local micro-
domains of very high [Ca2+]c as the ion enters through the
Ca2+-permeant NMDA channels, generating NO which in
combination with the [Ca2+]c signal is toxic to the cells.
Importantly, cells could be rescued by nNOS inhibition or
by decoupling the nNOS from the NMDA receptor.
This process is probably not an experimental oddity of
neurons in tissue culture but is thought to occur in the brain
under pathological conditions. The clearest role is in ischae-
mic disease in the CNS—in stroke for example—where
glutamate can rapidly accumulate in the extracellular space
to toxic concentrations of hundreds of micromolar. It is
believed that this mechanism is likely responsible for the
progression of a stroke over the first few days after an
ischaemic episode, extending the areas of brain injury
beyond the core ischaemic zone into a penumbra. What
completed the circle very nicely was the demonstration by
Tymianski and colleagues that decoupling nNOS from the
NMDA receptors using small peptides rendered membrane
permeant with the HIV TAT sequence rescued CNS tissue in
an in vivo stroke model [1].
The source specificity of glutamate-induced neuronal
damage has been refined more recently to suggest that
excessive activation of extrasynaptic receptors may induce
toxic Ca2+ loads and mitochondrial Ca2+-dependent injury,
whilst activation of synaptic receptors tends to cause smaller
Ca2+ elevations that play a prosurvival role [61], suggesting
that the balance between these two pathways may be critical
in some disease models, in which glutamate ‘overspill’ from
synaptic release, glutamate release from glial cells by rever-
sal of the glutamate transporter, or impaired glutamate clear-
ance from synaptic clefts might lead to overactivation of
extrasynaptic receptors, causing cell injury.
So, where do the mitochondria come in? One of the
major features of [Ca2+]c-dependent toxicity is the ‘delayed
deregulation of [Ca2+]c homeostasis’ (delayed [Ca
2+]c
deregulation, or DCD)—a secondary rise in [Ca2+]c that
can be delayed by anything from 1 or 2 to 10 min after the
initial exposure to glutamate (Fig. 1a). Simultaneous meas-
urements of mitochondrial membrane potential and [Ca2+]c
showed that the secondary [Ca2+]c deregulation occurs in
synchrony with a [Ca2+]c-dependent collapse of mitochon-
drial membrane potential (Δψm) [69] (Fig. 1a). The loss of
Δψm was preventable using nNOS inhibitors as was the
DCD, and indeed, mitochondria were sensitised to other-
wise innocuous [Ca2+]c loads by NO donors [39], suggest-
ing a direct link between the events at the plasma membrane
and routes to mitochondrial toxicity.
Key questions then are what are the mechanisms of DCD
and of loss of mitochondrial membrane potential? Once
mitochondrial potential is lost in a neuron, that cell is
destined to die as neurons have almost no capacity to
increase glycolytic ATP once oxidative phosphorylation is
lost [33], and so neurons with depolarized mitochondria will
undergo bioenergetic collapse and die. It has been generally
assumed that the loss of mitochondrial membrane potential
is triggered by mitochondrial Ca2+ accumulation (‘over-
load’), a state where influx into the mitochondria over-
whelms matrix Ca2+ buffering power and the capacity of
the sodium–calcium exchange efflux pathway. Direct meas-
urements of increased intramitochondrial free Ca2+ during
this process have proven remarkably difficult—transfection
of neurons with genetically encoded Ca2+ reporters is not
easy, and large intracellular pH shifts associated with the
massive movement of Na+ and Ca2+ across the membrane
introduce major artefacts into most measurements. Using
small molecule sensors such as rhod family dyes have also
failed in most people's hands, as dye loading invariably is
not restricted to the mitochondria and cytosolic [Ca2+]c rises
so high that the cytosolic component overwhelms the mito-
chondrial specific signal, which is probably saturated any-
way. It has been shown that brief exposure to uncoupler
around the time of glutamate application can be protective
[62]. The logic was that the uncoupler, by collapsing the
potential at the crucial time, prevents mitochondrial Ca2+
uptake. Even though the change in [Ca2+]c was if anything
enhanced, cell viability was improved, arguing that mito-
chondrial Ca2+ uptake plays a critical role in driving cell
death. This is a tricky experiment as uncouplers can only too
easily kill the cells, and so the timing is critical.
We showed relatively recently that inhibition of the Ca2+
uniporter using Ru360 prevented the loss of mitochondrial
membrane potential and decoupled DCD and mitochondrial
depolarization, as DCD proceeded even though mitochon-
drial potential was preserved [2] (Fig. 1b). This is perhaps
the closest so far to a direct demonstration of a role for
mitochondrial matrix Ca2+ overload as a determinant of
mitochondrial dysfunction (see also [21]). It would be ideal
to know whether this is protective against cell death, but
Ru360 is highly unstable and tricky to use—it is oxidised
rapidly after exposure to room air, and only ‘works’ for
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about 20–30 min after addition to the cells, making this an
impossible experiment, and as yet, the appropriate tools to
address this question directly are not available.
The mitochondrial permeability transition pore
Demonstrations of mitochondrial depolarization following a
rise in [Ca2+]m and dependent on nitrosative stress immedi-
ately flags involvement of the mitochondrial permeability
transition pore (mPTP) for any mitochondrial biologist.
Therefore it is timely to introduce the permeability transition
pore into this text. This is an extraordinary phenomenon,
which seems to underlie Ca2+-dependent mitochondrial cell
death in most tissues [31]. First described in a series of
remarkable papers by Haworth and Hunter [32, 34, 35], this
sudden loss of the mitochondrial permeability barrier fol-
lowing additions of Ca2+ or prooxidants was treated for a
long while as an artefact of isolated mitochondrial prepara-
tions. Much later, it was shown that the permeability
increase is due to the opening of a large conductance pore
in the inner mitochondrial membrane large enough to admit
deoxyglucose into the matrix and is not simply a disruption
of the membrane [30]. It has been suggested that the pore is
generated by a transformation of membrane proteins with other
physiological roles into a pore-forming configuration—
favoured candidates included the adenine nucleotide translo-
case (ANT), a protein which can switch to a pore-forming
conformation in the presence of high Ca2+ [57] and pore
opening is modulated by drugs which bind to the ANT, and
the voltage-dependent anion channel (VDAC) in the outer
mitochondrial membrane. However, recent experiments on
tissues from an ‘ANTand VDAC knockout mice’ have thrown
question marks over this model [6, 42] leaving considerable
uncertainty about the molecular identity of the mPTP. What is
clear and unambiguous is that the pore opening is regulated by
the matrix peptidyl prolyl cis–trans isomerase, the protein
cyclophilin D [5, 65]. This is particularly important, as it binds
to cyclosporine A (CsA), which prevents pore opening. CsA
has become the benchmark for mPTP opening and is now
being used in clinical trials for mPTP involvement (along with
other mPTP inhibitors) in various pathologies [28, 49].
The role of the mPTP in cell death during ischaemia and
reperfusion in the heart is clear and unambiguous. In the
CNS, the storey has been less straightforward. CsA proved
to be protective in stroke models [26] and in culture models
of glutamate toxicity. The problem is that CsA binds to all
cyclophilins, and these include cytosolic proteins that regu-
late calcineurin, which in turn mediates the Ca2+-dependent
activation of nNOS [20]. Given the role of nNOS described
above, this undermines the interpretation of experiments
that demonstrate any protective action of CsA and, in the
absence of other more specific pharmacological agents, has
made it difficult to assign an unambiguous role for mPTP in
glutamate toxicity or stroke. After generation of the CypD
knockout mouse, it was soon shown that infarct size was
reduced in the CypD knockout, arguing for a role for the
PTP in stroke and cell death in the CNS [5]. To our surprise,
however, the loss of mitochondrial potential in response to
glutamate was not notably altered in cell models from the
CypD knockout mouse [2], arguing that the initial loss of
potential cannot be a simple consequence of mPTP opening.
What we did find was that the loss of potential that was
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Fig. 1 Simultaneous measurements of [Ca2+]c (blue trace) and of
Δψm (red trace) from single hippocampal neurons in response to toxic
glutamate exposure. Δψm was measured using the dye rhodamine 123
which was used in the so-called ‘dequench’ mode, in which mitochon-
drial depolarization causes an increase in fluorescence signal. [Ca2+]c
was measured using fura-FF, a low affinity ratiometric [Ca2+]c indica-
tor. a The response to glutamate shows a stereotypical pattern: the
[Ca2+]c increases transiently followed by variable degree of recovery,
followed by a progressive increase—referred to as delayed [Ca2+]c
deregulation. Δψm changes only slightly during the initial phase, but
then the mitochondria show a progressive and complete depolarization
(addition of uncoupler which depolarises completely has no further
effect) that is exactly synchronous with DCD. b Following preincuba-
tion with Ru360, inhibitor of the mitochondrial uniporter, the [Ca2+]c
signal was essentially unchanged, but mitochondrial depolarization
was suppressed, suggesting that mitochondrial [Ca2+]c uptake is an
essential step on the pathway to [Ca2+]c-mediated cell death [2]
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knockout, suggesting that during a prolonged mitochondrial
depolarization there was a delayed transition from depolar-
ized mitochondria to mPTP opening [2].
A role for PARP?
This leaves the question of the cause of the initial mitochon-
drial depolarization caused by glutamate excitotoxicity. In
the late 1990s, evidence from several labs suggested that
glutamate toxicity engaged the enzyme PARP-1 [23, 43,
46]. Poly (ADP ribose) polymerase-1 is a DNA repair
enzyme that is activated by single strand DNA breaks,
usually the result of oxidative stress. Activation of PARP
uses NAD+ to generate polymers—poly (ADP ribose), or
PAR polymers—which are relatively shortlived as these are
rapidly degraded by the enzyme PAR Glycohydrolase [63].
It appears that PAR polymers can release apoptosis inducing
factor (AIF) from mitochondria, suggesting that cell death
may be mediated by AIF translocation to the nucleus and a
‘caspase-independent apoptosis’—a form of cell death that
has been termed ‘parthanatos’ [70]. This is a fascinating
model, but remains somewhat controversial. Several groups
have shown that PARP-1 is hyperactivated by glutamate
toxicity, but details of the pathways to cell death are less
clear. Thus, it has been proposed that activation of NMDA
receptors can activate the enzyme NADPH oxidase, gener-
ating oxidative stress that then activates PARP [10]. The
activation of PARP consumes NAD+, prevents cell metabo-
lism and the cells die. AIF may be released but seems
immaterial, as the cells will die through bioenergetic col-
lapse [3, 4]. In this model, it is hard to identify any specific
role for mitochondrial Ca2+ uptake or to see why preventing
mitochondrial Ca2+ uptake should be protective. Another
group have suggested that the oxidative stress that activates
PARP-1 is the result of mitochondrial Ca2+ uptake—i.e.
mitochondria take up Ca2+, the matrix Ca2+ overload gen-
erates excessive free radical species, this causes activation
of PARP-1 which then depletes NAD+ and the cells die [21].
Our own data suggest that mitochondrial Ca2+ uptake is
indeed critical for PARP-1 activation, and suggest that
PARP-1 activation causes the loss of mitochondrial mem-
brane potential by inhibition of glycolysis and so depletion
of mitochondrial substrate supply [2]. Thus, we found that
application of glutamate to neurons causes a remarkably
rapid decrease in the autofluorescence of NADH that pre-
cedes the loss of potential (Fig. 2a). Importantly, loss of
NADH and mitochondrial depolarization were prevented by
Ru360, (Fig. 2b) arguing that mitochondrial Ca2+ uptake is
an essential step on the pathway to PARP activation and to
cell death [2]. Pharmacological inhibition of PARP delayed
both the NADH oxidation and the loss of potential (Fig. 2c).
Remarkably, the mitochondrial membrane potential could
be restored using substrates that bypass glycolysis—pyru-
vate or methyl succinate for example, suggesting that mito-
chondrial depolarization occurs as a failure of substrate
supply as NAD+ is consumed and inhibits glycolytic supply
of pyruvate. Again, it was hard to see an essential role for
AIF, as the loss of potential condemns these cells to die. So
the precise role for AIF remains a little unclear. What again
brings the data full circle is the recent demonstration that
small molecule PARP inhibitors are protective in a stroke
model, putting the mechanism into a bigger context of brain
injury and stroke [51]. The proposed full pathways of exci-
totoxicity are illustrated schematically in Fig. 3.
Mitochondrial calcium handling and Parkinson's disease
Similar mechanisms of Ca2+-induced cell injury have been
implicated in the pathogenesis of PD. The dopaminergic
cells of the substantia nigra that degenerate in PD have an
unusual electrical feature as pacemaking neurons, in which
electrical activity is driven largely by L-type Ca2+ channels
[64]. It has been argued that this Ca2+-mediated activity
sensitises the pacemaking dopaminergic cells to injury, to
the extent that inhibition of L-type Ca2+ channels (a condi-
tion in which electrical activity is taken over by Na+-medi-
ated activity) can protect the cells against injury by toxins
such as 6-(OH)DA [15]. The specific role of downstream
pathways involving mitochondrial Ca2+ handling are per-
haps less clear. The Ca2+ load appears to increase mitochon-
drial free radical generation, which in normal mice induces a
protective mechanism through a mild uncoupling mecha-
nism mediated by the uncoupling proteins UCP3 and 4, with
the suggestion that this might reduce mitochondria free
radical generation and so serve a protective role. Thus, a
modest mitochondrial depolarization was inhibited by the
UCP antagonist genipin. Of greatest interest perhaps was the
loss of this protective mechanism by knockout of the protein
DJ-1 and protection by overexpression of DJ-1. DJ-1 (also
known as PARK7) is a protein in which mutations are
associated with early onset familial form of PD. The data
presented by the Surmeier group suggested that PTP and
CypD were not involved, but the mechanism of cell death
remains unclear [15]. Interestingly, other data also point to a
role for PARP in PD but again the specific link between
mitochondrial dysfunction, mitochondrial Ca2+ uptake, Ca2+
signalling and PARP does not seem to have been made
[36, 45].
Amongst the neurodegenerative diseases, the case for a
role of mitochondrial dysfunction in PD is probably the
strongest. Several models involving toxic damage to the
CNS, using the mitochondrial complex I inhibitor, rotenone,
the drug derived compound MPTP, which also blocks com-
plex I, and 6(OH)-DA, all cause mitochondrial and selective
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damage to dopaminergic neurons. Coupled with findings of
Complex I dysfunction in SN from post mortem material
from PD patients, it seems likely that this points to a major
role for mitochondrial bioenergetic dysfunction in PD [59].
Fig. 2 Simultaneous measurements of Δψm and of NADH autofluor-
escence from single hippocampal neurons. a Glutamate exposure
caused a rapid oxidation of NADH causing a decrease in signal (as
NAD+ is not fluorescent). Once the NADH oxidation reaches a nadir,
Δψm started to fall (an increase in fluorescence signal). Final addition
of uncoupler, FCCP, which causes maximal oxidation of mitochondrial
NADH had no effect, suggesting that the NADH pool was already
mostly oxidised. b Both the changes in Δψm and in NADH were
largely inhibited following preincubation with Ru360 and were pro-
foundly delayed by the PARP inhibitor 3-AB (c). Modified from [2]
Fig. 3 Scheme of pathways involved in glutamate-induced excitotox-
icity. Calcium influx through voltage-gated or NMDAR-gated chan-
nels is followed by mitochondrial Ca2+ influx through the
mitochondrial calcium uniporter (MCU). While the physiological con-
sequence of raised intramitochondrial [Ca2+] is an increased activity of
the three rate limiting enzymes of the TCA cycle, pathological and
prolonged Ca2+ influx leads to mitochondrial Ca2+overload. NMDAR-
mediated Ca2+ influx is closely coupled to the generation of NO by
nNOS; raised Ca2+ may activate the NADPH oxidase (Nox), while
mitochondrial Ca2+ overload may also increase generation of superox-
ide by the electron transport chain (ETC). Nitrosative or oxidative
stress arising either from the ETC or from Nox activation may cause
overactivation of PARP. PARP consumes NAD+to form PAR poly-
mers, causing depletion of NAD+, failure of glycolysis and so failure of
mitochondrial substrate supply. This culminates in the loss of Δψm,
ATP depletion and cell death. The PAR polymers generated by PARP
may also cause release of AIF which amplifies cell death following its
translocation to the nucleus
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Huge strides have been made in the genetics of familial PD
over recent years, with the identification of a string of
proteins in which mutations cause early onset PD (for a
review see: [25]). Remarkably, the picture that is emerging
from these studies again points towards a pivotal role for
mitochondrial dysfunction, as almost all of these proteins
seem either to associate with mitochondria or to lie on
mitochondrial associated pathways. Detailed discussion of
this literature and the proteins involved is outside the scope
of this essay, and I refer the reader to excellent recent
reviews for further detail [11, 12]. However, the notion that
the underlying defect may involve the failure of appropriate
removal of dysfunctional mitochondria allowing the slowly
progressive accumulation of mitochondrial defects as the
basis for a neurodegenerative disease [53] seems quite ap-
pealing, even though these proteins are ubiquitous and so
leaves us once again with the question why the dopaminer-
gic SN neurons should be especially vulnerable.
In our own work, we addressed the functional bioener-
getic consequences of a mutation of the protein PINK1 and
its consequences for the neuronal vulnerability to calcium-
mediated injury [27]. In PINK1 deficient cells, mitochon-
drial potential was reduced and was largely maintained by
the ATPase running in reverse mode. This state was reversed
by the provision of substrates for complex I and II (pyruvate
or methyl succinate), respectively, suggesting a defect in
substrate supply as a key mechanism underlying the bioen-
ergetic defect. We also found that mitochondrial Ca2+ efflux
was profoundly delayed in these cells, suggesting impaired
Na+/Ca2+ exchange in mitochondrial Ca2+ homeostasis. The
functional consequence of this defect was to make mito-
chondria far more vulnerable to Ca2+ overload and to dra-
matically reduce the effective threshold for mPTP opening,
leading to Ca2+-dependent cell death. At present, it is not
clear how to match these findings with our understanding of
a role for PINK1 as a regulator of mitochondrial autophagy,
unless we propose that the bioenergetic deficiencies are a
consequence of failure of autophagic removal of damaged
mitochondria. However, the observations provide a link
between the Ca2+ models of PD dysfunction and the emerg-
ing literature pointing towards mitochondrial dysfunction as
a pathophysiological mechanism in PD.
In Huntington's disease, there are also data suggesting that
the pathology involves increased mitochondrial sensitivity to
Ca2+ leading to a decreased threshold for mPTP opening.
Huntington's disease is caused by an expansion of exonic
CAG triplet repeats in the gene encoding the Huntingtin pro-
tein (Htt) that appear to be toxic. Mitochondria isolated from
the brains of transgenic mice expressing mutant Htt showed
depolarisation at lower Ca2+ loads than controls. Remarkably,
this observation could be replicated in normal mitochondria
exposed to long polyglutamine repeats, suggesting some kind
of direct sensitising effect of the mutant protein [55].
Motoneuron disease
The other major neurodegenerative disease that I must touch
on is Motoneuron disease, or ALS. This is an appalling
rapidly progressive and fatal disease involving the selective
degeneration of spinal motoneurons. As in PD, there are rare
familial forms of the disease which have been associated
with mutations of superoxide dismutase (mSOD-1) and
more recently with mutations of the protein vesicle associ-
ated membrane protein associated protein B (VAPB) [52].
The transgenic mutant mouse expressing the G93A mSOD-
1 mutation develops selective degeneration of spinal moto-
neurons, and so represents a very appealing model to study
ALS. There is always a major issue with using the mutations
associated with any of the familial forms of major neurode-
generative diseases in an attempt to understand the sporadic
disease which affects the majority of ALS patients. Familial
ALS (fALS) associated with the SOD-1 mutation accounts
for only a fraction of the total number of patients suffering
this horrible disease: the incidence of familial ALS is usu-
ally estimated at 5–10 % of all patients with ALS, of which
only one fifth express the SOD-1 mutation—i.e. this muta-
tion accounts for about 2 % of all ALS patients, and yet it is
the major model that is studied, if only for want of an
adequate model of the sporadic disease. It is hard to know
how much these studies will really tell us about the sporadic
disease, but there is no doubt that it does tell us a great deal
about general principles governing pathophysiological
mechanism.
There is a substantial literature suggesting that motoneu-
ron death in the mSOD-1 G93A genetic model of fALS is
associated with mitochondrial dysfunction and some evi-
dence linking changes in Ca2+ and mitochondrial Ca2+ over-
load. Thus, motoneurons express Ca2+-permeable AMPA
receptors and also appear to have a relatively low Ca2+
buffering capacity. Exposure of motoneurons to AMPA
caused increased ROS generation, loss of mitochondrial
potential and cell death [14]. Furthermore, motoneurons
expressing the G93A SOD-1 mutation were protected by
overexpression of the Ca2+-buffering protein, parvalbumin
[68], and also by knockdown of cyclophilin D [47], together
pointing towards mPTP-related mechanism of glutamate-
induced injury, mediated by AMPA receptors rather than
the NMDA receptors that drive glutamate toxicity in cortical
and hippocampal neurons. Interestingly, it seems that neuro-
degeneration in the fALS model is initiated at nerve termi-
nals and tracks back along the axons. Gathering evidence
suggests that Ca2+-mediated mitochondrial toxicity may be
associated with repetitive stimulation in peripheral moto-
neuron axons [7], perhaps operating exactly the same mech-
anisms discussed above. Indeed, there is some evidence for
a role of PARP in ALS as well, suggesting that elements of
this Ca2+-dependent mitochondrial cell death pathway are
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recapitulated in different diseases, perhaps shaped by the
specific physiology of each cell type [17, 40, 41].
There is also substantial evidence pointing to a distur-
bance in mitochondrial axonal transport in fALS. Thus, the
VAPB mutation also seems to target Ca2+ and mitochondria
but relating to mitochondrial transport in axons. A general
defect in retrograde axonal transport has been described in
the axons of G93A mutant mice, preceding the onset of
symptoms, while a selective defect of anterograde axonal
mitochondrial transport and a decrease in axonal mitochon-
drial content has also been described in the G93A mutant
[52]. The VAPB mutation (VAPB P56S) also causes a selec-
tive defect in anterograde transport of mitochondria in axons
associated with a rise in local [Ca2+]c, probably related to ER
disruption (VAPB is an ER protein). The local elevation of
the [Ca2+]c signal regulates Miro1-mediated axonal mito-
chondrial transport (see above) leading to impaired mito-
chondrial trafficking and distribution. It is not clear why
this defect should selectively affect motoneurons, nor why
it should lead ultimately to motoneuron degeneration.
Conclusions
Mitochondrial dysfunction is clearly implicated in the path-
ogenesis of the major neurodegenerative diseases and plays
a critical role as a determinant of irreversible cell injury
following stroke. Increasing evidence suggests that special-
isations of Ca2+ signalling pathways in different cell types
may play a major role in shaping the patterns of cell loss in
each of the major neurodegenerative diseases. Understand-
ing these pathways brings the promise of defining new
potential therapeutic targets for these dreadful diseases.
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